Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Raised to Hold at Wall Street Zen

Fulcrum Therapeutics (NASDAQ:FULC) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, October 15th. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, Fulcrum Therapeutics currently has a consensus rating of “Reduce” and a consensus target price of $8.20.

Fulcrum Therapeutics Trading Up 2.4%

FULC stock opened at $3.77 on Friday. Fulcrum Therapeutics has a one year low of $2.83 and a one year high of $15.74. The firm has a 50-day moving average of $3.73 and a two-hundred day moving average of $5.55. The firm has a market capitalization of $287.95 million, a PE ratio of -3.62 and a beta of 2.82.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, equities research analysts anticipate that Fulcrum Therapeutics will post -0.60 earnings per share for the current year.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of large investors have recently made changes to their positions in FULC. BlackRock Inc. purchased a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth about $32,297,000. Bank of America Corp DE bought a new stake in shares of Fulcrum Therapeutics in the 2nd quarter valued at approximately $3,817,000. Bank of New York Mellon Corp bought a new stake in shares of Fulcrum Therapeutics in the 2nd quarter valued at approximately $566,000. Siren L.L.C. increased its holdings in Fulcrum Therapeutics by 20.5% in the first quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock worth $18,024,000 after buying an additional 400,000 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in Fulcrum Therapeutics in the second quarter worth approximately $20,038,646. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.